Reviewed by Christian Espinosa, MBA, CISSP · Founder & CEO
Published April 2026 · Last reviewed May 2026
Episode 69 · The Med Device Cyber Podcast · with Varun Turlapati, Chaanakya Capital · April 17, 2026 This episode of The Med Device Cyber Podcast features Varun Turlapati of Chaanakya Capital, offering an investor’s perspective on the MedTech landscape, particularly in neurotechnology. Turlapati emphasizes the critical importance of foundational science and technology in early-stage medical device innovation, cautioning against "sham devices" and highlighting the need for clinical validation. The discussion pivots to a crucial, often-overlooked aspect: cybersecurity. Turlapati, recognizing his software engineering background, acknowledges the initial perception of cybersecurity as a burden by innovators focused on features and rapid deployment. However, both he and the host stress that neglecting cybersecurity in medical devices carries severe risks, far exceeding typical B2B SaaS data loss - potentially leading to loss of life. They advocate for integrating cybersecurity early in the product lifecycle, ideally at the due diligence phase for investors, to prevent costly reworks and ensure regulatory compliance with bodies like the FDA. The conversation underscores that proactive cybersecurity, though seemingly an added cost, ultimately safeguards patient safety, builds public trust, and is indispensable for MedTech companies pursuing regulatory clearance and long-term success.
Key Takeaways
- Varun Turlapati prioritizes foundational science, technology, and clinical validation in MedTech investments, specifically in neurotechnology.
- Early integration of cybersecurity in medical device development is crucial to prevent potentially life-threatening risks and costly reworks.
- Consulting with cybersecurity experts early in the design phase can prevent significant financial and technical challenges later on.
- Neglecting cybersecurity can result in substantial rework costs and regulatory non-compliance, jeopardizing product launch and patient safety.
- Investors and innovators must collaborate to ensure cybersecurity is addressed proactively, hardening products and building public trust.
- The unique challenges and profound impact of neurotechnology underscore the need for robust cybersecurity measures from inception.
- The speaker advocates for investors to challenge founders on their cybersecurity strategies during due diligence to ensure product integrity and patient safety.
Listen on mdcpodcast.com · Watch on YouTube
Listen to this episode
Want help applying this to your own device program?
Blue Goat Cyber is a specialist medical device cybersecurity firm: 250+ FDA submissions, zero rejections. If anything in this conversation hit close to home, book a 30-minute strategy session - no cost, no obligation.